{"id":"W3208128184","doi":"10.1182/blood-2021-146820","title":"Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Daratumumab; Bortezomib; AL amyloidosis; Medicine; Amyloidosis; Dexamethasone; Cyclophosphamide; Internal medicine; Melphalan; Andromeda; Immunoglobulin light chain; Phases of clinical research; Oncology; Multiple myeloma; Dermatology; Antibody; Immunology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004148928,0.001016832,0.002052566,0.0003862662,0.0004003062,0.001333537,0.0005706914,0.0008870207,0.00109115],"category_scores_gemma":[0.00197701,0.0004543049,0.003193788,0.0006412275,0.0005844588,0.0007561208,0.0004207804,0.002187839,0.0002915587],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008005461,"about_ca_system_score_gemma":0.001266995,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006845901,"about_ca_topic_score_gemma":0.001460318,"domain_scores_codex":[0.9985301,0.0008467147,0.00009140421,0.0002244011,0.0001671888,0.0001400049],"domain_scores_gemma":[0.997465,0.0005151472,0.000832307,0.0001570077,0.0001724491,0.0008580413],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8171921,0.01039374,0.09741172,0.000722127,0.005862809,0.0003462569,0.0002161265,0.001530857,0.01089361,0.0001222698,0.001951491,0.05335675],"study_design_scores_gemma":[0.4309743,0.261245,0.2926863,0.0001415403,0.004815664,0.001028504,0.0001205678,0.002074298,0.001880823,0.0002240072,0.004702945,0.0001059267],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909366,0.006799444,0.0002404305,0.000263226,0.00008201546,0.0004261586,0.0007173892,0.00002666713,0.0005082371],"genre_scores_gemma":[0.9953429,0.00129976,0.0005488138,0.0004029395,0.0001469018,0.0003237514,0.001629661,0.000007825721,0.0002974096],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004148928,"threshold_uncertainty_score":0.0219419,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.004616778762143049,"score_gpt":0.2290357377421151,"score_spread":0.224418958979972,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}